Eledon Pharmaceuticals (ELDN)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	6.75 mm	6.75 mm	6.75 mm	6.75 mm	6.75 mm	6.75 mm
Cash burn (monthly)	6.43 mm	(no burn)	6.84 mm	4.68 mm	3.92 mm	3.12 mm
Cash used (since last report)	32.56 mm	n/a	34.62 mm	23.72 mm	19.86 mm	15.79 mm
Cash remaining	-25.80 mm	n/a	-27.87 mm	-16.97 mm	-13.11 mm	-9.04 mm
Runway (months of cash)	-4.0	n/a	-4.1	-3.6	-3.3	-2.9

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2024

ELDN institutional ownership history Ownership history

81.7% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	78	16	+387.5%
Opened positions	63	2	+3050.0%
Closed positions	1	19	-94.7%
Increased positions	7	6	+16.7%
Reduced positions	1	1	–

13F shares	Current	Prev Q	Change
Total value	157.96 bn	7.10 bn	+2124.8%
Total shares	48.79 mm	9.13 mm	+434.1%
Total puts	2.70 k	0.00	NEW
Total calls	17.00 k	0.00	NEW
Total put/call ratio	0.2	–	–

Largest owners	Shares	Value	Change
Biotechnology Value Fund L P	6.29 mm	$29.33 mm	0.0%
BVF	6.29 mm	$25.93 bn	NEW
Ra Capital Management	3.57 mm	$14.69 bn	NEW
Armistice Capital	3.14 mm	$15.00 mm	NEW
Vanguard	2.89 mm	$11.93 bn	+84.9%
Sphera Funds Management	2.55 mm	$10.51 bn	NEW
First Light Asset Management	2.33 mm	$9.59 bn	NEW
Blue Owl Capital	1.96 mm	$8.07 bn	NEW
Woodline Partners	1.67 mm	$6.89 bn	NEW
Schonfeld Strategic Advisors	1.52 mm	$6.24 bn	NEW

Largest transactions	Shares	Bought/sold	Change
BVF	6.29 mm	+6.29 mm	NEW
Ra Capital Management	3.57 mm	+3.57 mm	NEW
Armistice Capital	3.14 mm	+3.14 mm	NEW
Sphera Funds Management	2.55 mm	+2.55 mm	NEW
First Light Asset Management	2.33 mm	+2.33 mm	NEW
Blue Owl Capital	1.96 mm	+1.96 mm	NEW
Woodline Partners	1.67 mm	+1.67 mm	NEW
Schonfeld Strategic Advisors	1.52 mm	+1.52 mm	NEW
Vanguard	2.89 mm	+1.33 mm	+84.9%
Ensign Peak Advisors	1.26 mm	+1.26 mm	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

ELDN insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
10 Jan 25	John S. McBride	RSU Common Stock	Grant	Acquire A	No	No	0	3,430	0.00	3,430
10 Jan 25	John S. McBride	Stock Option Common Stock	Grant	Acquire A	No	No	4.04	30,870	124.71 k	30,870
10 Jan 25	Smith Bryan E.	RSU Common Stock	Grant	Acquire A	No	No	0	64,500	0.00	64,500
10 Jan 25	Smith Bryan E.	Stock Option Common Stock	Grant	Acquire A	No	No	4.04	150,500	608.02 k	150,500
10 Jan 25	June Lee	RSU Common Stock	Grant	Acquire A	No	No	0	3,430	0.00	3,430
10 Jan 25	June Lee	Stock Option Common Stock	Grant	Acquire A	No	No	4.04	30,870	124.71 k	30,870
10 Jan 25	Allan Kirk	RSU Common Stock	Grant	Acquire A	No	No	0	3,430	0.00	3,430
10 Jan 25	Allan Kirk	Stock Option Common Stock	Grant	Acquire A	No	No	4.04	30,870	124.71 k	30,870
10 Jan 25	Katkin Keith	RSU Common Stock	Grant	Acquire A	No	No	0	8,575	0.00	8,575
10 Jan 25	Katkin Keith	Stock Option Common Stock	Grant	Acquire A	No	No	4.04	77,175	311.79 k	77,175

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Press releases

From Benzinga Pro

Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human

7 Feb 25

Patient treated in procedure, conducted at Mass General Transplant Center and in collaboration with partner eGenesis, was recently released from hospital Investigational therapy tegoprubart targets CD40 ligand (CD40L)

Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference

29 Jan 25

IRVINE, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, and Steve Perrin, Ph.D., Chief